25th Sep 2008 07:00
Correction - Results of the Annual General Meeting held on September 24, 2008
Correction for the announcement made on September 24, 2008. Two paragraphs were truncated from the original announcement.
Dublin, Ireland - September 25, 2008 - Shire Limited , the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:
For* Against Withheld** 1. To elect Mr Matthew 301,376,910 4,696,170 25,441,808 Emmens as a Director of the Company 2. To elect Mr Angus 331,225,599 138,229 151,060 Russell as a Director of the Company 3. To elect Mr Graham 331,234,635 127,173 153,080 Hetherington as a Director of the Company 4. To elect Dr Barry Price 328,858,454 2,501,778 154,656 as a Director of the Company 5. To elect Mr David 330,945,634 412,470 156,784 Kappler as a Director of the Company 6. To elect Dr Jeffrey 331,221,109 138,828 154,951 Leiden as a Director of the Company 7. To elect Mr Patrick 330,949,493 412,089 153,306 Langlois as a Director of the Company 8. To elect Ms Kate Nealon 331,014,606 346,949 153,333 as a Director of the Company 9. To elect Mr David Mott 327,884,774 2,101,928 1,528,186 as a Director of the Company 10. To elect Dr Michael 331,232,603 126,815 155,470 Rosenblatt as a Director of the Company 11. To re-appoint Deloitte 327,634,578 1,301,388 2,578,922 & Touche LLP as Auditors of the Company 12. To authorise the Audit, 331,225,599 1,470,679 159,584 Compliance and Risk Committee to determine the remuneration of the Auditors 13. To authorise the 328,104,104 3,189,130 221,654 allotment of shares 14. To authorise the 329,760,418 1,575,955 178,515 disapplication of pre-emption rights 15. To authorise market 330,598,450 729,745 186,693 purchases 16. To change the name of 331,323,817 31,609 159,462 the Company to Shire plc
* These figures include discretionary votes
** A vote "withheld" is not a vote in law and is not counted in the calculation of the votes "for" or "against" a resolution.
Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.
The change of name of the Company to Shire plc is expected to become effective on October 1, 2008, following the registration of the change with Companies Registry in Jersey.
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Jessica Cotrone (North America) +1 617 613 4640 Notes to editorsSHIRE LIMITED
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
vendorRelated Shares:
Shire